Recently, there has been great interest in the potential utility of NF-L in blood as a biomarker for several neurodegenerative diseases including AD, MS, progressive supranuclear palsy (PSP), ALS, and Huntington’s disease [43, 71, 228, 240, 302, 385, 408], as well as a marker of traumatic brain injury [224, 324]. Here, NEFL is linked to myeloid sarcoma.